TABLE 1

Demographic and other patient characteristics: safety analysis set

PlaceboAZD5069Total
Subjects n262652
Age years65±8.866±6.665±7.7
Female12 (46.2)16 (61.5)28 (53.8)
White Caucasian26 (100)26 (100)52 (100)
Weight kg77±17.075±15.876±16.3
Height cm168±9.6166±8.3167±8.9
BMI kg·m−227.4±6.226.7±4.127.1±5.2
Duration of bronchiectasis# years13±21.822±22.917.5±22.6
Type of bronchiectasis
  Purulent sputum (Pseudomonas aeruginosa)4 (15.4)6 (23.1)10 (19.2)
  Purulent sputum (non-Pseudomonas aeruginosa)16 (61.5)17 (65.4)33 (63.5)
  Mucoid sputum5 (19.2)3 (11.5)8 (15.4)
Lung function (FEV1 on day 1) L1.88±0.961.52±0.541.70
Nicotine use
  Never14 (53.8)12 (46.2)26 (50.0)
  Former10 (38.5)10 (38.5)20 (38.5)
  Current2 (7.7)4 (15.4)6 (11.5)
Prior COPD diagnosis4 (15.4)6 (23.1)10 (19.2)
Concomitant medications
  Salbutamol14 (53.8)17 (65.4)31 (59.6)
  Fluticasone + salmeterol9 (34.6)9 (34.6)18 (34.6)
  Paracetamol1 (3.8)8 (30.8)9 (17.3)
  Carbocisteine5 (19.2)6 (23.1)11 (21.2)
  Budesonide + formoterol2 (7.7)5 (19·2)7 (13.5)
  Ramipril1 (3.8)5 (19.2)6 (11.5)
  Tiotropium bromide2 (7.7)4 (15.4)6 (11.5)
  Tiotropium5 (19.2)3 (11.5)8 (15.4)
  Omeprazole6 (23.1)4 (15.4)10 (19.2)
  Azithromycin3 (11.5)4 (15.4)7 (13.5)
  Acetylsalicylic acid6 (23.1)2 (7.7)8 (15.4)
  • Data are presented as n, mean±sd or n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 s; COPD: chronic obstructive pulmonary disease. #: duration of bronchiectasis is calculated as the date of screening minus the date bronchiectasis first appeared; : used by >15% of patients.